Read + Share
Amedeo Smart
Independent Medical Education
Xu B. Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy - Author's reply. Lancet Oncol 2023;24:e357.PMID: 37657472
Email
LinkedIn
Facebook
Twitter
Privacy Policy